Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07445022) titled 'RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
Melanoma Advanced
Intervention:
Drug: tunlametinib
Recruitment Status: Recruiting
Phase: Phase 4
Date of First Enrollment: January 28, 2026
Target Sample Size: 110
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07445022
Published by HT Digital Content Services with permission from Health Daily ...